| 2021-05-06 | Kirchgraber Paul R | CEO, Covance Drug Development | Sell | 2,500 | $276.55 | $691,375.00 | -24.2% | → |
| 2021-05-03 | BELINGARD JEAN-LUC | Director | Sale+OE | 2,600 | $269.16 | $699,803.26 | -14.3% | → |
| 2021-03-30 | Schroeder Mark S | EVP, President-Diagnostics Lab | Sell | 667 | $251.88 | $168,003.96 | -11.8% | → |
| 2021-03-30 | van der Vaart Sandra D | EVP, Chief Legal Officer | Sell | 812 | $251.88 | $204,526.56 | -13.4% | → |
| 2021-02-18 | Wilkinson Peter J | SVP, Chief Accounting Officer | Sale+OE | 2,317 | $241.51 | $559,589.33 | -87.1% | → |
| 2021-02-16 | van der Vaart Sandra D | EVP, Chief Legal Officer | Sale+OE | 208 | $236.55 | $49,201.63 | -1.5% | → |
| 2021-02-16 | Schroeder Mark S | EVP, President-Diagnostics Lab | Sale+OE | 188 | $237.06 | $44,567.28 | -2.1% | → |
| 2021-02-05 | van der Vaart Sandra D | EVP, Chief Legal Officer | Sale+OE | 109 | $225.85 | $24,617.65 | -2.5% | → |
| 2021-02-05 | Schroeder Mark S | EVP, President-Diagnostics Lab | Sale+OE | 203 | $225.85 | $45,847.55 | -4.7% | → |
| 2020-11-06 | Schroeder Mark S | EVP, President-Diagnostics Lab | Sell | 588 | $214.59 | $126,178.92 | -13.0% | → |
| 2020-11-04 | Kirchgraber Paul R | CEO, Covance Drug Development | Sell | 1,500 | $214.14 | $321,203.55 | -16.3% | → |
| 2020-07-08 | Williams R Sanders | Director | Sale+OE | 1,300 | $173.12 | $225,056.00 | -20.3% | → |
| 2020-07-02 | van der Vaart Sandra D | EVP, Chief Legal Officer | Sell | 435 | $170.00 | $73,950.00 | -9.7% | → |
| 2020-06-24 | van der Vaart Sandra D | EVP, Chief Legal Officer | Sell | 872 | $160.33 | $139,807.76 | -8.5% | → |
| 2020-05-05 | KING DAVID P | Director | Sell | 31,250 | $160.00 | $5,000,000.00 | -9.1% | → |
| 2020-03-10 | Seltz Judith C | EVP, CHRO | Buy | 580 | $171.31 | $99,359.80 | +232.0% | → |
| 2020-02-21 | Wilkinson Peter J | SVP, Chief Accounting Officer | Sell | 297 | $189.65 | $56,325.72 | -50.0% | → |
| 2020-02-19 | BELINGARD JEAN-LUC | Director | Sale+OE | 26,479 | $189.76 | $5,024,750.36 | -64.3% | → |
| 2020-02-13 | van der Vaart Sandra D | SVP, Global General Counsel | Sale+OE | 208 | $188.49 | $39,205.92 | -3.6% | → |
| 2020-02-13 | Schroeder Mark S | EVP, President-Diagnostics Lab | Sale+OE | 188 | $188.49 | $35,436.12 | -14.9% | → |
| 2020-02-13 | Williams R Sanders | Director | Sale+OE | 1,227 | $188.49 | $231,277.23 | -19.4% | → |
| 2020-02-10 | Schroeder Mark S | EVP, President-Diagnostics Lab | Sale+OE | 108 | $181.99 | $19,654.92 | -26.4% | → |
| 2020-02-10 | van der Vaart Sandra D | SVP, Global General Counsel | Sale+OE | 133 | $181.99 | $24,204.67 | -5.0% | → |
| 2019-10-28 | KING DAVID P | President & CEO | Sell | 30,177 | $165.40 | $4,991,216.89 | -3.1% | → |
| 2019-09-23 | ANDERSON KERRII B | Director | Sale+OE | 2,600 | $171.85 | $446,810.00 | -12.7% | → |
| 2019-09-04 | Uthgenannt Lisa J | Chief Human Resources Officer | Sale+OE | 2,466 | $168.59 | $415,742.94 | -34.6% | → |
| 2019-08-30 | BERBERIAN LANCE | SVP, Chief Information Officer | Sell | 5,902 | $169.80 | $1,002,171.99 | -49.2% | → |
| 2019-08-05 | Williams R Sanders | Director | Sell | 500 | $162.91 | $81,455.00 | -6.8% | → |
| 2019-07-08 | EISENBERG GLENN A | Chief Financial Officer, EVP | Sell | 5,563 | $176.75 | $983,260.25 | -24.6% | → |
| 2019-07-08 | van der Vaart Sandra D | SVP, Global General Counsel | Sell | 2,328 | $176.75 | $411,474.00 | -50.0% | → |
| 2019-06-20 | ANDERSON KERRII B | Director | Sale+OE | 3,100 | $170.00 | $527,000.00 | -13.9% | → |
| 2019-06-07 | EISENBERG GLENN A | Chief Financial Officer, EVP | Sell | 10,000 | $167.40 | $1,673,969.53 | -11.8% | → |
| 2019-05-06 | Williams R Sanders | Director | Sell | 500 | $162.20 | $81,100.00 | -6.3% | → |
| 2019-05-03 | MITTELSTAEDT ROBERT E JR | Director | Sale+OE | 3,700 | $166.30 | $615,310.00 | -19.6% | → |
| 2019-05-02 | Uthgenannt Lisa J | Chief Human Resources Officer | Sell | 4,000 | $164.00 | $656,000.00 | -46.3% | → |
| 2019-02-12 | BELINGARD JEAN-LUC | Director | Sale+OE | 3,700 | $146.06 | $540,406.83 | -10.1% | → |